Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...
The developers of OpenFold3 have released an early version of the tool, which they hope will one day perform on par with DeepMind’s protein-structure model.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback